Table 3.
Types of single alloantibodies
| 2014 (%) | 2015 (%) | 2016 (%) | 2017 (%) | 2018 (%) | 2019 (%) | 2020 (%) | |
|---|---|---|---|---|---|---|---|
| Anti-D* | 4 (25) | 25 (39.7) | 33 (31.1) | 54 (43.2) | 76 (39.8) | 87 (52.7) | 62 (57.9) |
| Anti-E | 3 (18.8) | 6 (9.5) | 15 (14.2) | 14 (11.2) | 15 (7.9) | 15 (9.1) | 11 (10.3) |
| Anti-C | 1 (6.3) | 4 (6.3) | 10 (9.4) | 18 (14.4) | 16 (8.4) | 4 (2.4) | 1 (0.9) |
| Anti-c | 2 (12.5) | 4 (6.3) | 12 (11.3) | 4 (3.2) | 16 (8.4) | 10 (6.1) | 8 (7.5) |
| Anti-e | 0 | 0 | 1 (0.9) | 0 | 3 (1.6) | 0 | 3 (2.8) |
| Anti-K | 1 (6.3) | 1 (1.6) | 4 (3.8) | 0 | 5 (2.6) | 1 (0.6) | 0 |
| Anti-Fya | 0 | 1 (1.6) | 2 (1.9) | 3 (2.4) | 3 (1.6) | 6 (3.6) | 2 (1.9) |
| Anti-Fyb | 0 | 1 (1.6) | 0 | 1 (0.8) | 0 | 0 | 0 |
| Anti-Jka | 0 | 0 | 3 (2.8) | 3 (2.4) | 2 (1) | 0 | 2 (1.9) |
| Anti-Jkb | 0 | 0 | 0 | 0 | 1 (0.5) | 0 | 1 (0.9) |
| Anti-Lea | 0 | 4 (6.3) | 4 (3.8) | 4 (3.2) | 9 (4.7) | 11 (6.7) | 3 (2.8) |
| Anti-Leb | 2 (12.5) | 4 (6.3) | 5 (4.7) | 3 (2.4) | 12 (6.3) | 3 (1.8) | 2 (1.9) |
| Anti-M | 3 (18.8) | 7 (11.1) | 12 (11.3) | 17 (13.6) | 31 (16.2) | 22 (13.3) | 10 (9.3) |
| Anti-N | 0 | 1 (1.6) | 0 | 1 (0.8) | 0 | 0 | 0 |
| Anti-S | 0 | 1 (1.6) | 3 (2.8) | 1 (0.8) | 0 | 1 (0.6) | 2 (1.9) |
| Anti-s | 0 | 2 (3.2) | 0 | 0 | 0 | 1 (0.6) | 0 |
| Anti-P1 | 0 | 2 (3.2) | 2 (1.9) | 2 (1.6) | 2 (1) | 3 (1.8) | 0 |
| Anti-Kpa | 0 | 0 | 0 | 0 | 0 | 1 (0.6) | 0 |
| Total | 16 (100) | 63 (100) | 106 (100) | 125 (100) | 191 (100) | 165 (100) | 107 (100) |
*For anti D – P<0.001 (significant). Anti-D showed a significant increase over the years. χ2=140.742 with 102° of freedom, P=0.007 (significant)